Home Title Index Topic Index Sources Directory News Releases Sources Calendar RSS Sources Select News RSS Feed

Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer's Disease
Sources News Release

http://www.sources.com/Releases/NR1208.htm

Publisher:  Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written:  21/03/2011
Year Published:  2011  
Resource Type:  Article

Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The

Abstract:  ANAVEX 2-73 trial to be initiated immediately in Germany

Hoboken, NJ – March 15, 2011 -- Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase...
To read the full release go to http://www.sources.com/Releases/NR1208.htm

Topics


Sources-journalists use the sources website to find you


AlterLinks
c/o Sources


© 2019. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.